1. Scrip
  2. >>Business

India CEO Pay: Up, Up For Most, Eye On Gender Pay Gap As Women Execs Rise

 
• By Anju Ghangurde

C-suite remuneration at leading listed foreign and domestic drug firms in India rose in double digits for the most part in 2022-23, data compiled by Scrip show. While MDs/CEOs at domestic firms continue to take home sizeably higher earnings, the arrival of women leaders at the helm in some foreign firms puts the spotlight on gender pay parity.

CEO pay in India - Going, Going Higher • Source: Shutterstock

C-suite remuneration across over a dozen pharma companies in India, moved upwards in 2022-23, save a few exceptions, with top-level compensation at local firms continuing to, by and large, dwarf comparable earnings at foreign listed entities in the country.

CEOs and managing directors of domestic firms, for the most part, took home larger pay packets, with Zydus Lifesciences Limited’s MD Sharvil Patel, leading the league table in 2022-23 with remuneration of INR262

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

BeiGene To Trade Beach For Chalet In Swiss Redomiciling As BeOne

 
• By Alaric DeArment

The biotech saw a slight quarter-over-quarter decline in sales from the BTK inhibitor Brukinsa, which it attributed to seasonality, while revenues overall missed some analyst estimates.

Industry Makes Its Case To Trump In Effort To Sidestep Tariffs

 
• By Jessica Merrill

Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a 232 investigation.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.